Backers included Viking Global Investors via the Illumina Accelerator Boost Capital, Matrix Capital Management, Alexandria Venture Investments, SV Tech Ventures and China Rock Capital Management.
The company intends to use the funds to develop alternatives to small-molecule antibiotics for use in agriculture, to invest in its microbiome engineering platform, and to file for additional patents on its technology.
Led by CEO Dr. Nick Conley, COO Aaron Tynes Hammack, PhD, CSO Christina Tsai, PhD, CMO Lucia Mokres, DVM, and CTO Bruno Marchon, PhD, EpiBiome develops FDA-approved therapies to combat infectious disease in humans and in agriculture without the use of small-molecule antibiotics. Its first product will address bovine mastitis, an inflammation of the udder tissue in dairy cows, usually caused by bacterial infection, which results in $35 billion and $2 billion in losses to the global and US dairy industries, respectively, due to reduced milk production and milk quality.
FinSMEs
04/02/2016